110 related articles for article (PubMed ID: 26010159)
1. Nonpegylated liposomal doxorubicin: reduction in cardiotoxicity, although still severe alopecia.
van den Hurk C; Breed W; Dercksen W
Anticancer Drugs; 2015 Jul; 26(6):687. PubMed ID: 26010159
[No Abstract] [Full Text] [Related]
2. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.
Tahover E; Patil YP; Gabizon AA
Anticancer Drugs; 2015 Mar; 26(3):241-58. PubMed ID: 25415656
[TBL] [Abstract][Full Text] [Related]
3. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
4. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
Theodoulou M; Hudis C
Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
[TBL] [Abstract][Full Text] [Related]
5. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review.
Fojtu M; Gumulec J; Stracina T; Raudenska M; Skotakova A; Vaculovicova M; Adam V; Babula P; Novakova M; Masarik M
Curr Drug Metab; 2017; 18(3):237-263. PubMed ID: 28059036
[TBL] [Abstract][Full Text] [Related]
6. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
7. Safety aspects of pegylated liposomal doxorubicin in patients with cancer.
Alberts DS; Garcia DJ
Drugs; 1997; 54 Suppl 4():30-5. PubMed ID: 9361959
[TBL] [Abstract][Full Text] [Related]
8. Melatonin: a protective role against doxorubicin-induced cardiotoxicity.
Govender J; Loos B; Engelbrecht AM
Future Oncol; 2015; 11(14):2003-6. PubMed ID: 26198826
[No Abstract] [Full Text] [Related]
9. Liposomal co-delivered oleanolic acid attenuates doxorubicin-induced multi-organ toxicity in hepatocellular carcinoma.
Sarfraz M; Afzal A; Raza SM; Bashir S; Madni A; Khan MW; Ma X; Xiang G
Oncotarget; 2017 Jul; 8(29):47136-47153. PubMed ID: 28525367
[TBL] [Abstract][Full Text] [Related]
10. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).
Working PK; Dayan AD
Hum Exp Toxicol; 1996 Sep; 15(9):751-85. PubMed ID: 8880211
[No Abstract] [Full Text] [Related]
12. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
13. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
14. Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.
Morisco A; Accardo A; Tesauro D; Palumbo R; Benedetti E; Morelli G
Biopolymers; 2011; 96(1):88-96. PubMed ID: 20560147
[TBL] [Abstract][Full Text] [Related]
15. Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.
Visani G; Isidori A
Expert Rev Anticancer Ther; 2009 Mar; 9(3):357-63. PubMed ID: 19275512
[TBL] [Abstract][Full Text] [Related]
16. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.
Jakoby J; Beuschlein F; Mentz S; Hantel C; Süss R
Oncotarget; 2015 Dec; 6(41):43698-711. PubMed ID: 26497207
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products.
Yu J; Wang C; Kong Q; Wu X; Lu JJ; Chen X
Phytomedicine; 2018 Feb; 40():125-139. PubMed ID: 29496165
[TBL] [Abstract][Full Text] [Related]
19. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes).
Jain S; Patil SR; Swarnakar NK; Agrawal AK
Mol Pharm; 2012 Sep; 9(9):2626-35. PubMed ID: 22871060
[TBL] [Abstract][Full Text] [Related]
20. The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review.
Razavi-Azarkhiavi K; Iranshahy M; Sahebkar A; Shirani K; Karimi G
Nutr Cancer; 2016; 68(6):892-917. PubMed ID: 27341037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
